Dr. Reddy’s launches drug-free migraine management device Nerivio® in Europe following successful launch in India

Hyderabad India; April 11, 2024 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company, announced the launch of the drug-free non-invasive migraine management wearable device Nerivio® in Germany through its step-down subsidiary beta pharm. The launch marks the company’s entry into digital therapeutics in Europe. Nerivio® is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe.

Dr. Reddy's- building

Nerivio® was presented in 2023 by Dr. Reddy at the DGN Kongress organised by the German Association of Neurology in Berlin, and the 17th European Headache Congress held in Barcelona, Spain. Dr. Reddy will present and launch Nerivio® during the Neurological Association of South Africa annual congress on April 17, 2024, in the presence of Dr. Stewart Tepper, Professor of Neurology at the Geisel School of Medicine – Dartmouth, and Vice President, New England Institute for Neurology and Headache. In May 2024, Nerivio® will also be presented at the International Headache Society 2024 iHEAD meeting in Berlin, Germany. In subsequent months, Dr. Reddy’s will launch Nerivio® in Spain and the UK.

Last year, Dr. Reddy entered into an exclusive agreement with Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, for the marketing and distribution of Nerivio® in multiple markets.

Migraine is a global health challenge, affecting around 30% of adults on 15 or more days per month, impacting 1.7% to 4% of the population. The current best estimate of global migraine prevalence is 14–15%, and, in terms of burden, migraine accounts for 4.9% of global ill health, quantified as years lived with disability. Migraines are known to have a disproportionate impact on women. Around 8 to 10 million people in Germany are affected, 14.8% of women and 6.0% of men. In India, women constitute approximately 60% of the 213 million migraine sufferers.

Dr. Reddy’s launched Nerivio® in India in 2023. In India, Nerivio® is supported by Dr. Reddy’s unique patient support program called ‘M-Free’. The program is a comprehensive support system that enhances and streamlines the journey of the patients. M-Free includes services such as onboarding and counseling of patients, device demonstrations, doorstep delivery, flexible payment options, informative content, and dedicated customer care to help patients get the most out of the device. With lifestyle modification as a key recommendation for better management of migraine, the M-Free awareness program offers a suite of value-added services such as nutritionist consultation, yoga, and meditation sessions with certified specialists for holistic medicine-free migraine management.

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s said, “At a time when conversations on migraine focus on migraine as a women’s health issue, relief from migraine through the use of technology and drug-free solutions, challenges associated with managing migraine during the child-bearing age, and distinguishing migraine from headache, we are happy to take our clinically-proven first digital therapeutics product, Nerivio®, to patients in our identified markets. Nerivio® has had an encouraging start in India, with recommendation from neurologists in India and bringing relief to patients living with migraine. We believe this product meets a genuine unmet clinical need among migraine patients, and has the potential to reduce pill burden in migraine. We look forward to receiving patient and HCP feedback from these markets.”

You May Also Like

More From Author

+ There are no comments

Add yours